The Vanguard Group 13D and 13G filings for Atossa Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-12 1:32 pm Unchanged |
2024-09-30 | 13G | Atossa Therapeutics, Inc. ATOS |
The Vanguard Group | 6,598,296 5.240% |
0 (Unchanged) |
Filing |
| 2024-11-04 11:27 am Purchase |
2024-09-30 | 13G | Atossa Therapeutics, Inc. ATOS |
The Vanguard Group | 6,598,296 5.240% |
900,760 (+15.81%) |
Filing |
| 2023-02-09 11:07 am Sale |
2022-12-30 | 13G | Atossa Therapeutics, Inc. ATOS |
The Vanguard Group | 5,697,536 4.500% |
-1,273,314 (-18.27%) |
Filing |
| 2022-02-09 3:24 pm Purchase |
2021-12-31 | 13G | Atossa Therapeutics, Inc. ATOS |
The Vanguard Group | 6,970,850 5.510% |
6,970,850 (New Position) |
Filing |